Pharma Mar Sau Stock Net Income
| PHMMF Stock | USD 88.72 1.84 2.03% |
As of the 10th of February, Pharma Mar holds the Risk Adjusted Performance of (0.04), coefficient of variation of (1,691), and Variance of 1.22. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pharma Mar, as well as the relationship between them. Please check Pharma Mar SAU market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Pharma Mar SAU is priced some-what accurately, providing market reflects its current price of 88.72 per share. Given that Pharma Mar has total risk alpha of (0.20), we recommend you to check out Pharma Mar SAU's recent market performance to make sure the company can sustain itself at a future point.
Pharma Mar's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Pharma Mar's valuation are provided below:Pharma Mar SAU does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Pharma |
Pharma Mar 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Pharma Mar's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Pharma Mar.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Pharma Mar on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Pharma Mar SAU or generate 0.0% return on investment in Pharma Mar over 90 days. Pharma Mar is related to or competes with Neuren Pharmaceuticals, Genus Plc, PeptiDream, Oxford Nanopore, Mesoblast, CStone Pharmaceuticals, and Green Thumb. Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization o... More
Pharma Mar Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Pharma Mar's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Pharma Mar SAU upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 7.16 | |||
| Value At Risk | (0.12) |
Pharma Mar Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharma Mar's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Pharma Mar's standard deviation. In reality, there are many statistical measures that can use Pharma Mar historical prices to predict the future Pharma Mar's volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.20) | |||
| Treynor Ratio | 1.8 |
Pharma Mar February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | 1.81 | |||
| Mean Deviation | 0.3093 | |||
| Coefficient Of Variation | (1,691) | |||
| Standard Deviation | 1.1 | |||
| Variance | 1.22 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.20) | |||
| Treynor Ratio | 1.8 | |||
| Maximum Drawdown | 7.16 | |||
| Value At Risk | (0.12) | |||
| Skewness | (3.12) | |||
| Kurtosis | 31.32 |
Pharma Mar SAU Backtested Returns
At this point, Pharma Mar is very steady. Pharma Mar SAU maintains Sharpe Ratio (i.e., Efficiency) of 0.0692, which implies the firm had a 0.0692 % return per unit of risk over the last 3 months. We have found nineteen technical indicators for Pharma Mar SAU, which you can use to evaluate the volatility of the company. Please check Pharma Mar's Risk Adjusted Performance of (0.04), variance of 1.22, and Coefficient Of Variation of (1,691) to confirm if the risk estimate we provide is consistent with the expected return of 0.0476%. Pharma Mar has a performance score of 5 on a scale of 0 to 100. The company holds a Beta of -0.0417, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Pharma Mar are expected to decrease at a much lower rate. During the bear market, Pharma Mar is likely to outperform the market. Pharma Mar SAU right now holds a risk of 0.69%. Please check Pharma Mar SAU variance, as well as the relationship between the value at risk and day median price , to decide if Pharma Mar SAU will be following its historical price patterns.
Auto-correlation | 0.37 |
Below average predictability
Pharma Mar SAU has below average predictability. Overlapping area represents the amount of predictability between Pharma Mar time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Pharma Mar SAU price movement. The serial correlation of 0.37 indicates that just about 37.0% of current Pharma Mar price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.37 | |
| Spearman Rank Test | -0.02 | |
| Residual Average | 0.0 | |
| Price Variance | 3.17 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Pharma Mar SAU reported net income of 92.86 M. This is 72.79% lower than that of the Healthcare sector and 32.57% higher than that of the Biotechnology industry. The net income for all United States stocks is 83.74% higher than that of the company.
Pharma Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharma Mar's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Pharma Mar could also be used in its relative valuation, which is a method of valuing Pharma Mar by comparing valuation metrics of similar companies.Pharma Mar is currently under evaluation in net income category among its peers.
Pharma Fundamentals
| Return On Equity | 0.47 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.35 % | |||
| Operating Margin | 0.33 % | |||
| Current Valuation | 1.12 B | |||
| Shares Outstanding | 18.09 M | |||
| Shares Owned By Insiders | 26.95 % | |||
| Shares Owned By Institutions | 10.48 % | |||
| Price To Earning | 7.38 X | |||
| Price To Book | 5.60 X | |||
| Price To Sales | 5.57 X | |||
| Revenue | 229.83 M | |||
| Gross Profit | 213.39 M | |||
| EBITDA | 104.08 M | |||
| Net Income | 92.86 M | |||
| Cash And Equivalents | 196.7 M | |||
| Cash Per Share | 10.92 X | |||
| Total Debt | 33.39 M | |||
| Debt To Equity | 0.21 % | |||
| Current Ratio | 2.86 X | |||
| Book Value Per Share | 9.88 X | |||
| Cash Flow From Operations | 25.68 M | |||
| Earnings Per Share | 4.97 X | |||
| Number Of Employees | 477 | |||
| Beta | 0.12 | |||
| Market Capitalization | 1.26 B | |||
| Total Asset | 368.39 M | |||
| Retained Earnings | (17 M) | |||
| Working Capital | 32 M | |||
| Current Asset | 110 M | |||
| Current Liabilities | 78 M | |||
| Z Score | 22.2 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 368.39 M | |||
| Last Dividend Paid | 0.65 |
About Pharma Mar Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharma Mar SAU's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharma Mar using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharma Mar SAU based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Pharma Pink Sheet
Pharma Mar financial ratios help investors to determine whether Pharma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharma with respect to the benefits of owning Pharma Mar security.